Abstract
BACKGROUND: Various blood safety initiatives have ensured a historically low risk of infection transmission through blood transfusion. Although further prevention of infection transmission is possible through, for example, nucleic acid testing and future introduction of pathogen inactivation, such initiatives are very costly in relation to the benefit they offer. Although estimation of the cost-effectiveness requires detailed information about the survival of transfusion recipients, previous cost-effectiveness analyses have relied on incorrect survival assumptions. STUDY DESIGN AND METHODS: Based on empirical data of more than 1 million Scandinavian transfusion recipients followed for up to 20 years, we present two new survival functions. In a fictitious example we assessed the impact of survival assumptions on the estimated costs per quality-adjusted life-year (QALY) gained, by using the survival functions of three previous cost-effectiveness analyses along with the two new survival functions. CONCLUSIONS: We conclude that despite considerable costs, previous cost-effectiveness studies may have underestimated the costs per QALY gained by as much as 44%.
| Original language | English |
|---|---|
| Journal | Transfusion |
| Volume | 50 |
| Issue number | 1 |
| Pages (from-to) | 240-2 |
| Number of pages | 3 |
| ISSN | 0041-1132 |
| DOIs | |
| Publication status | Published - Jan 2010 |
Keywords
- Blood Banks
- Blood Transfusion
- Cost-Benefit Analysis
- Follow-Up Studies
- Humans
- Infection
- Infection Control
- Quality of Health Care
- Quality-Adjusted Life Years
- Risk Factors
- Scandinavia
- Survival Analysis
